Table 1.
Clinical characteristics of patients with and without statin intolerance
| All N = 952 |
Statin Intolerance N = 138 |
No Statin Intolerance N = 814 |
P-value | |
|---|---|---|---|---|
| Age, years | 66 ± 11 | 67 ± 10 | 66 ± 11 | 0.79 |
| Age ≥ 65 years, n (%) | 558 (58.6) | 81 (58.7) | 477 (58.6) | 0.98 |
| Male, n (%) | 696 (73.1) | 99 (71.7) | 597 (73.3) | 0.70 |
| Current smoker, n (%) | 160 (16.8) | 25 (18.1) | 135 (16.6) | 0.66 |
| Hypertension, n (%) | 716 (75.2) | 107 (77.5) | 609 (74.8) | 0.49 |
| Diabetes mellitus, n (%) | 336 (35.3) | 61 (44.2) | 275 (33.8) | 0.02 |
| Type of statin at baseline | ||||
| Simvastatin, n (%) | 537 (56.4) | 82 (59.4) | 455 (55.9) | 0.50 |
| Atorvastatin, n (%) | 179 (18.8) | 21 (15.2) | 158 (19.4) | |
| Rosuvastatin, n (%) | 236 (24.8) | 35 (25.4) | 201 (24.7) | |
| Statin dose at baseline (simvastatin dose equivalent) | ||||
| 10 mg, n (%) | 227 (23.8) | 30 (21.7) | 197 (24.2) | 0.91 |
| 20 mg, n (%) | 365 (38.3) | 56 (40.6) | 309 (38.0) | |
| 40 mg, n (%) | 254 (26.7) | 36 (26.1) | 218 (26.8) | |
| 80 mg, n (%) | 106 (11.1) | 16 (11.6) | 90 (11.1) | |
| Baseline lipid profile* | ||||
| Total cholesterol, mmol/L | 4.1 ± 1.0 | 4.2 ± 1.1 | 4.0 ± 1.0 | 0.08 |
| Triglyceride, mmol/L | 1.5 ± 1.0 | 1.7 ± 1.2 | 1.5 ± 1.0 | < 0.01 |
| HDL-C, mmol/L | 1.2 ± 0.4 | 1.2 ± 0.5 | 1.2 ± 0.3 | 0.78 |
| LDL-C, mmol/L | 2.1 ± 0.8 | 2.2 ± 0.9 | 2.1 ± 0.8 | 0.71 |
| LDL-C < 1.8 mmol/L, n (%) | 359 (37.7) | 49 (35.5) | 310 (38.1) | 0.56 |
| Non-HDL-C, mmol/L | 2.9 ± 1.0 | 3.0 ± 1.0 | 2.8 ± 1.0 | 0.09 |
| Ln hs-cTnI, pg/ml | 2.2 ± 1.4 | 2.6 ± 1.6 | 2.1 ± 1.3 | < 0.01 |
| Type of statin at follow-up | ||||
| Simvastatin, n (%) | 626 (65.8) | 93 (67.4) | 533 (65.5) | 0.41 |
| Atorvastatin, n (%) | 145 (15.2) | 16 (11.6) | 129 (15.9) | |
| Rosuvastatin, n (%) | 181 (19.0) | 29 (21.0) | 152 (18.7) | |
| Statin dose at follow-up (simvastatin dose equivalent) | ||||
| 10 mg, n (%) | 280 (29.4) | 39 (28.3) | 241 (29.6) | 0.84 |
| 20 mg, n (%) | 378 (39.7) | 55 (39.9) | 323 (39.7) | |
| 40 mg, n (%) | 203 (21.3) | 28 (20.3) | 175 (21.5) | |
| 80 mg, n (%) | 91 (9.6) | 16 (11.6) | 75 (9.2) | |
| Other lipid lowering therapy at follow-up | ||||
| Ezetimible, n (%) | 32 (3.4) | 8 (5.8) | 24 (3.0) | 0.09 |
| Fibrate, n (%) | 82 (8.6) | 14 (10.1) | 68 (8.4) | 0.49 |
| Lipid profile at follow-up | ||||
| Total cholesterol, mmol/L | 3.7 ± 0.8 | 3.9 ± 1.0 | 3.7 ± 0.7 | < 0.01 |
| Triglyceride, mmol/L | 1.4 ± 0.9 | 1.6 ± 1.1 | 1.3 ± 0.8 | < 0.01 |
| HDL-C, mmol/L | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.2 ± 0.4 | 0.09 |
| LDL-C, mmol/L | 1.9 ± 0.6 | 2.0 ± 0.8 | 1.9 ± 0.6 | 0.01 |
| LDL-C < 1.8 mmol/L, n (%) | 412 (43.3) | 51 (37.0) | 361 (44.4) | 0.11 |
| Non-HDL-C, mmol/L | 2.5 ± 0.7 | 2.7 ± 0.9 | 2.5 ± 0.7 | < 0.01 |
*Baseline lipid profile was taken after the diagnosis of CAD was confirmed by coronary angiography
Abbreviations: HDL-C high density lipoprotein cholesterol, hs-cTnl high-sensitive cardiac troponin I, Ln natural logarithm, LDL-C low density lipoprotein cholesterol